Lithium ER 300 mg Three Times Daily: Dosing Appropriateness and Monitoring
Lithium extended-release 300 mg three times daily (total 900 mg/day) is an acceptable dosing regimen, though current evidence supports once-daily evening dosing as preferable for improved tolerability and compliance while maintaining equivalent efficacy.
Dosing Considerations
Standard Dosing Parameters
According to FDA labeling, acute mania typically requires 600 mg three times daily (1800 mg/day total) to achieve therapeutic serum levels of 1.0-1.5 mEq/L, while maintenance therapy usually requires 300 mg 3-4 times daily (900-1200 mg/day) to maintain levels of 0.6-1.2 mEq/L 1. Your proposed regimen of 300 mg three times daily falls within the maintenance range.
However, the specific 900 mg/day total dose may be insufficient for many patients. The FDA label indicates that elderly patients often require reduced dosages and may exhibit toxicity at levels ordinarily tolerated by younger patients 1. Typical maintenance doses are:
- Age <40 years: 925-1300 mg/day
- Age 40-60 years: 740-925 mg/day
- Age >60 years: 550-740 mg/day 2
Frequency of Administration: Once Daily vs. Multiple Daily Doses
The evidence strongly favors once-daily evening dosing over three-times-daily administration. Multiple studies demonstrate that single daily dosing:
- Produces equivalent antimanic efficacy with no significant difference in symptom control 3, 4
- Significantly reduces urinary frequency and polyuria (a major tolerability issue) 4
- Improves medication compliance by eliminating midday doses 5, 3
- May reduce long-term renal damage risk 5
- Results in transient higher peak concentrations but no increase in clinically significant side effects 3
The three-times-daily schedule offers no demonstrated clinical advantage, and the midday dose creates compliance challenges 2.
Extended-Release vs. Immediate-Release Formulations
Extended-release formulations reduce peak serum concentrations by 30-50% without changing total drug exposure, which theoretically improves tolerability 2. However, systematic comparisons show SR formulations may be better tolerated with possibly greater treatment adherence, though comparative efficacy studies are lacking 6.
For extended-release formulations, target serum concentrations should be maintained at 0.8-1.0 mEq/L rather than 0.6-0.8 mEq/L (recommended for immediate-release) due to the delayed peak 2.
Critical Monitoring Requirements
Baseline Assessment (Before Starting Lithium)
Mandatory baseline laboratory tests include 7, 1:
- Complete blood count
- Thyroid function tests (TSH, free T4)
- Renal function: BUN, creatinine, urinalysis
- Serum calcium
- Pregnancy test in females of childbearing age
Serum Lithium Level Monitoring
During acute phase: Check lithium levels twice weekly until stable 1
During maintenance: Check levels at least every 2 months in uncomplicated cases 1, though some guidelines recommend every 3 months 7
Timing of blood draws is critical:
- For immediate-release formulations: Draw 12 hours post-dose
- For extended-release once-daily dosing: Draw 24 hours post-dose 8
- For extended-release multiple daily dosing: Draw 12 hours post-last-dose 8
This timing is essential because extended-release formulations achieve 90% absorption by 4 hours and 100% by 8 hours, with serum levels at 12 hours being essentially identical to immediate-release formulations 8.
Ongoing Monitoring Schedule
Every 3-6 months, monitor 7:
- Serum lithium level
- Renal function (BUN, creatinine, urinalysis)
- Thyroid function (TSH)
- Hematological indices
At each visit, assess for 1:
- Signs of toxicity: diarrhea, vomiting, tremor, ataxia, drowsiness, muscular weakness
- Adequate hydration status (2500-3000 mL fluid intake daily)
- Normal salt intake maintenance
Weight and Metabolic Monitoring
If lithium is combined with atypical antipsychotics (common in bipolar disorder), additional metabolic monitoring is required 7:
- Body mass index: Monthly for 3 months, then quarterly
- Blood pressure, fasting glucose, lipid panel: At 3 months, then yearly
Critical Drug Interactions and Contraindications
Avoid or use with extreme caution 9, 1:
- NSAIDs: Can increase lithium levels by 17% or more; indomethacin and piroxicam particularly problematic 1
- Diuretics: Reduce renal lithium clearance, increasing toxicity risk 1
- ACE inhibitors: Increase lithium levels through sodium loss 1
- Haloperidol: Risk of encephalopathic syndrome; monitor closely if combined 1
Renal impairment considerations:
- Contraindicated if GFR <30 mL/min/1.73 m² (based on general CKD medication guidelines) 9
- Requires dose reduction and increased monitoring if renal function declines 1
Pregnancy: Lithium is Category D—contraindicated due to teratogenic risk 1
Recommended Approach
For a new patient, I recommend:
- Start with 300 mg once daily in the evening (not three times daily)
- Increase by 300 mg every 3-7 days as tolerated
- Target total daily dose of 900-1200 mg (given as single evening dose)
- Check lithium level 12 hours post-dose for immediate-release or 24 hours post-dose for extended-release once-daily dosing
- Target serum level: 0.8-1.0 mEq/L for extended-release formulations
- Monitor twice weekly until stable, then every 2-3 months
If the patient is already taking 300 mg three times daily:
- Consider consolidating to 900 mg once daily in the evening
- This maintains the same total daily dose while improving tolerability and compliance
- Recheck lithium level 5-7 days after schedule change
Common Pitfalls to Avoid
- Drawing lithium levels at incorrect times (must be 12 hours for IR or multiple-dose ER; 24 hours for once-daily ER)
- Failing to adjust for renal function decline (elderly patients particularly vulnerable)
- Not educating patients about maintaining adequate hydration and salt intake (2500-3000 mL fluid daily)
- Missing drug interactions with NSAIDs (very common, can precipitate toxicity)
- Inadequate monitoring frequency during dose adjustments or intercurrent illness